202 related articles for article (PubMed ID: 26544581)
1. Disclosure of pharmacokinetic drug results to understand nonadherence.
van der Straten A; Montgomery ET; Musara P; Etima J; Naidoo S; Laborde N; Hartmann M; Levy L; Bennie T; Cheng H; Piper J; Grossman CI; Marrazzo J; Mensch B;
AIDS; 2015 Oct; 29(16):2161-71. PubMed ID: 26544581
[TBL] [Abstract][Full Text] [Related]
2. Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?
Mensch BS; Brown ER; Liu K; Marrazzo J; Chirenje ZM; Gomez K; Piper J; Patterson K; van der Straten A
AIDS Behav; 2016 Nov; 20(11):2654-2661. PubMed ID: 26906023
[TBL] [Abstract][Full Text] [Related]
3. Misreporting of Product Adherence in the MTN-003/VOICE Trial for HIV Prevention in Africa: Participants' Explanations for Dishonesty.
Montgomery ET; Mensch B; Musara P; Hartmann M; Woeber K; Etima J; van der Straten A
AIDS Behav; 2017 Feb; 21(2):481-491. PubMed ID: 27858268
[TBL] [Abstract][Full Text] [Related]
4. Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.
van der Straten A; Brown ER; Marrazzo JM; Chirenje MZ; Liu K; Gomez K; Marzinke MA; Piper JM; Hendrix CW;
J Int AIDS Soc; 2016; 19(1):20642. PubMed ID: 26850270
[TBL] [Abstract][Full Text] [Related]
5. Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.
Corneli A; Perry B; McKenna K; Agot K; Ahmed K; Taylor J; Malamatsho F; Odhiambo J; Skhosana J; Van Damme L
J Acquir Immune Defic Syndr; 2016 Apr; 71(4):452-61. PubMed ID: 26536315
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers.
Bardon AR; Simoni JM; Layman LM; Stekler JD; Drain PK
AIDS Res Ther; 2020 Aug; 17(1):50. PubMed ID: 32762713
[TBL] [Abstract][Full Text] [Related]
7. Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017.
Balán IC; Giguere R; Brown W; Carballo-Diéguez A; Horn S; Hendrix CW; Marzinke MA; Ayudhya RPKN; Patterson K; Piper JM; McGowan I; Lama JR; Cranston RD;
AIDS Behav; 2018 Mar; 22(3):986-995. PubMed ID: 29076032
[TBL] [Abstract][Full Text] [Related]
8. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
9. Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study.
Wynne J; Muwawu R; Mubiru MC; Kamira B; Kemigisha D; Nakyanzi T; Kabwigu S; Nakabiito C; Kiweewa Matovu F
HIV Clin Trials; 2018 Oct; 19(5):165-171. PubMed ID: 30370830
[TBL] [Abstract][Full Text] [Related]
10. Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study.
Luecke EH; Cheng H; Woeber K; Nakyanzi T; Mudekunye-Mahaka IC; van der Straten A;
J Int AIDS Soc; 2016; 19(1):20875. PubMed ID: 27247202
[TBL] [Abstract][Full Text] [Related]
11. High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.
Carballo-Diéguez A; Balán IC; Brown W; Giguere R; Dolezal C; Leu CS; Marzinke MA; Hendrix CW; Piper JM; Richardson BA; Grossman C; Johnson S; Gomez K; Horn S; Kunjara Na Ayudhya RP; Patterson K; Jacobson C; Bekker LG; Chariyalertsak S; Chitwarakorn A; Gonzales P; Holtz TH; Liu A; Mayer KH; Zorrilla C; Lama J; McGowan I; Cranston RD
PLoS One; 2017; 12(7):e0181607. PubMed ID: 28750059
[TBL] [Abstract][Full Text] [Related]
12. Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial.
Musinguzi N; Muwonge T; Thomas K; Baeten JM; Bangsberg DR; Haberer JE
AIDS Behav; 2016 Nov; 20(11):2639-2643. PubMed ID: 26781865
[TBL] [Abstract][Full Text] [Related]
13. The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study.
Velloza J; Khoza N; Scorgie F; Chitukuta M; Mutero P; Mutiti K; Mangxilana N; Nobula L; Bulterys MA; Atujuna M; Hosek S; Heffron R; Bekker LG; Mgodi N; Chirenje M; Celum C; Delany-Moretlwe S;
J Int AIDS Soc; 2020 Mar; 23(3):e25463. PubMed ID: 32144874
[TBL] [Abstract][Full Text] [Related]
14. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa.
van der Straten A; Stadler J; Montgomery E; Hartmann M; Magazi B; Mathebula F; Schwartz K; Laborde N; Soto-Torres L
PLoS One; 2014; 9(2):e89118. PubMed ID: 24586534
[TBL] [Abstract][Full Text] [Related]
15. Pre-exposure Prophylaxis Adherence Measured by Plasma Drug Level in MTN-001: Comparison Between Vaginal Gel and Oral Tablets in Two Geographic Regions.
Minnis AM; van der Straten A; Salee P; Hendrix CW
AIDS Behav; 2016 Jul; 20(7):1541-8. PubMed ID: 25969178
[TBL] [Abstract][Full Text] [Related]
16. How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe.
Musara P; Montgomery ET; Mgodi NM; Woeber K; Akello CA; Hartmann M; Cheng H; Levy L; Katz A; Grossman CI; Chirenje ZM; van der Straten A; Mensch B;
AIDS Behav; 2018 Mar; 22(3):877-886. PubMed ID: 28110473
[TBL] [Abstract][Full Text] [Related]
17. Social Context of Adherence in an Open-Label 1 % Tenofovir Gel Trial: Gender Dynamics and Disclosure in KwaZulu-Natal, South Africa.
MacQueen KM; Dlamini S; Perry B; Okumu E; Sortijas S; Singh C; Pillay D; Majors A; Jerome S; Watson S; Karim SA; Karim QA; Mansoor LE
AIDS Behav; 2016 Nov; 20(11):2682-2691. PubMed ID: 26945585
[TBL] [Abstract][Full Text] [Related]
18. Acceptability of lifelong treatment among HIV-positive pregnant and breastfeeding women (Option B+) in selected health facilities in Zimbabwe: a qualitative study.
Chadambuka A; Katirayi L; Muchedzi A; Tumbare E; Musarandega R; Mahomva AI; Woelk G
BMC Public Health; 2017 Jul; 18(1):57. PubMed ID: 28743251
[TBL] [Abstract][Full Text] [Related]
19. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.
Mirembe BG; Kelly CW; Mgodi N; Greenspan S; Dai JY; Mayo A; Piper J; Akello CA; Kiweewa FM; Magure T; Nakabiito C; Marrazzo JM; Chirenje ZM; Riddler SA;
J Acquir Immune Defic Syndr; 2016 Mar; 71(3):287-94. PubMed ID: 26866954
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Gaur AH; Kizito H; Prasitsueubsai W; Rakhmanina N; Rassool M; Chakraborty R; Batra J; Kosalaraksa P; Luesomboon W; Porter D; Shao Y; Myers M; Ting L; SenGupta D; Quirk E; Rhee MS
Lancet HIV; 2016 Dec; 3(12):e561-e568. PubMed ID: 27765666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
